Ace%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520inhibitors

# ACE Inhibitors ## Overview Angiotensin-converting enzyme (ACE) inhibitors are a class of medications primarily used for managing cardiovascular conditions. They work by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, leading to vasodilation and reduced blood pressure. ## Primary Indications * Hypertension * Heart Failure (with reduced ejection fraction) * Acute Myocardial Infarction (in select patients) * Diabetic Nephropathy (to slow progression) * Chronic Kidney Disease (proteinuric) ## Adult Dosing Dosing varies by specific agent, indication, and patient response. Common starting doses and typical maintenance doses include: * **Benazepril:** Start 5-10 mg once daily; Max 40 mg/day. * **Captopril:** Start 6.25-12.5 mg TID; Max 50 mg TID. * **Enalapril:** Start 2.5-5 mg once or twice daily; Max 40 mg/day. * **Fosinopril:** Start 10 mg once daily; Max 80 mg/day. * **Lisinopril:** Start 5-10 mg once daily; Max 40 mg/day. * **Moexipril:** Start 7.5 mg once daily; Max 30 mg/day. * **Perindopril:** Start 2.5-5 mg once daily; Max 10 mg/day. * **Quinapril:** Start 5-10 mg once or twice daily; Max 80 mg/day. * **Ramipril:** Start 2.5 mg once daily; Max 10 mg/day. * **Trandolapril:** Start 0.5-1 mg once daily; Max 4 mg/day. ## Pediatric Dosing Established pediatric dosing is available for some ACE inhibitors, but use should be guided by specific guidelines and expert consultation. * **Enalapril:** 0.07-0.1 mg/kg/dose orally every 12-24 hours; Max 0.5 mg/kg/day. * **Captopril:** 0.3-0.5 mg/kg/dose orally every 8 hours; Max 1.5 mg/kg/day (max 50 mg/dose). Dosing for other ACE inhibitors in pediatrics may be less well-established and typically requires careful titration based on response and tolerability. ## Dose Adjustments * **Renal Impairment:** Dose reduction is often necessary, especially for agents renally cleared. Specific recommendations vary by drug and degree of renal impairment. For example, captopril and enalapril may require significant dose reduction in moderate to severe renal insufficiency. * **Hepatic Impairment:** Use with caution. Some agents may require lower starting doses. * **Volume Depletion/Hyponatremia:** Start with lower doses. ## Contraindications * History of angioedema related to previous ACE inhibitor treatment. * Hereditary or idiopathic angioedema. * Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment. * Pregnancy (Category D in 2nd and 3rd trimesters, Category X in 1st trimester). ## Adverse Effects * **Common:** Cough (dry, persistent), dizziness, hypotension, hyperkalemia, fatigue, headache, rash. * **Serious:** Angioedema (potentially life-threatening), acute kidney injury (especially in patients with bilateral renal artery stenosis), severe hypotension, hyperkalemia. ## Key Drug Interactions * **Potassium-Sparing Diuretics (e.g., spironolactone, amiloride) & Potassium Supplements:** Increased risk of hyperkalemia. * **NSAIDs:** May reduce antihypertensive effect and increase risk of renal impairment, especially in elderly or volume-depleted patients. * **Diuretics (especially loop and thiazide):** Increased risk of symptomatic hypotension upon initiation. * **Lithium:** ACE inhibitors can decrease lithium clearance, leading to lithium toxicity. * **mTOR Inhibitors (e.g., sirolimus, everolimus) & DPP-4 Inhibitors (e.g., sitagliptin):** Increased risk of angioedema. * **Aliskiren:** Contraindicated in patients with diabetes or renal impairment due to increased risk of adverse events including hyperkalemia and renal impairment. ## Monitoring * **Blood Pressure:** Regular monitoring to assess efficacy and prevent hypotension. * **Renal Function (Serum Creatinine & BUN):** Baseline and periodically, especially in patients with pre-existing renal disease or risk factors. * **Serum Potassium:** Baseline and periodically, especially in patients with renal impairment, hyperkalemia risk factors, or concomitant use of potassium-sparing agents. * **Angioedema Symptoms:** Educate patients to report any signs immediately. ## Clinical Pearls * The characteristic dry cough is due to increased bradykinin levels and may necessitate discontinuation of the ACE inhibitor and switching to an alternative agent (e.g., ARB). * Initiate with low doses, especially in volume-depleted patients, those on diuretics, or with renal impairment, to minimize the risk of profound hypotension. * Monitor for hyperkalemia, particularly in patients with impaired renal function, diabetes, or those taking potassium supplements or potassium-sparing diuretics. * ACE inhibitors are generally considered renoprotective in patients with proteinuria, but close monitoring of renal function is essential. * Discontinue ACE inhibitors immediately if angioedema occurs. --- ***Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always consult current prescribing information and a qualified healthcare provider for definitive guidance on drug use, dosing, and patient management.*